Ocrevus (ocrelizumab) delayed disability progression and worsening hand function among a large group of people with primary progressive multiple sclerosis (PPMS), including those who were older and had more advanced disease. The data, which come from the Phase 3 ORATORIO-HAND trial (NCT04035005), were presented by Jiwon Oh,…

The experimental drug fenebrutinib was shown to significantly outperform Aubagio (teriflunomide), an approved therapy, in reducing relapses and MRI markers of disease activity in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from a pair of largely identical Phase 3 clinical trials…

Patient enrollment is complete in a Phase 3 trial testing a new formulation of Briumvi (ublituximab-xiiy), TG Therapeutics‘ multiple sclerosis (MS) medication for relapsing forms of the disease, that could be injected at home. The new formulation is designed to be given under the skin, or subcutaneously, every…

The first participant has been dosed in a Phase 1 clinical trial testing TNV262, an experimental therapy that Tenvie Therapeutics is developing as a potential treatment for multiple sclerosis (MS) and other conditions including obesity and cardiovascular disease. The Phase 1a/1b study will test single and multiple doses…

The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can…

Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase 2 clinical trial of Lucid-MS, a “first-in-class” oral therapy designed to halt the progression of multiple sclerosis (MS) by protecting myelin, or the protective sheath around nerves in…

Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the progressive…

IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was well tolerated in healthy volunteers when given at single increasing doses. The findings come from the single-ascending dose portion of an ongoing Phase 1 clinical trial (NCT06637865), which tested…

The Accelerated Cure Project for Multiple Sclerosis (ACP) has received funding to help interpret and share findings from the DISCO-MS study, which examined whether older adults with stable multiple sclerosis (MS) could stop disease-modifying medications, to support more informed treatment decisions. The award comes through the Eugene Washington…

Innocare Pharma has dosed the first healthy volunteer in a clinical trial in China testing ICP-538, its oral treatment candidate for multiple sclerosis (MS) and other autoimmune diseases. The novel experimental therapy works by promoting the degradation of the VAV1 protein, essential for the function of T-cells and…